Skip to main content

Leadership

News Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quarter of 2019:

  • JP Morgan – 2018 CEO Conference Call Series
    Virtual/Conference Call (information to be provided by JP Morgan)
    November 13, 2018

  • Three Part Advisors – 2018 Southwest IDEAS Investor Conference
    Dallas, TX
    November 14-15, 2018

  • Piper Jaffray – 30th Annual Healthcare Conference
    New York, NY
    November 27-29, 2018

  • Mizuho – Global Mizuho Investor Conference
    New York, NY
    December 3, 2018

  • BMO Capital Markets – 2018 Prescriptions for Success Healthcare Conference
    New York, NY
    December 12, 2018

  • JP Morgan – 37th Annual Healthcare Conference
    San Francisco, CA
    January 7-10, 2019

Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as the information becomes available.
For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com

emergent logo.jpg

Emergent BioSolutions